Abstract. Aberrant expression of the claudin family of proteins has been reported in many human cancers, including pancreatic ductal carcinoma. Intraductal papillary mucinous neoplasms of the pancreas (IPMN) and mucinous cystic neoplasms (MCN) are considered precancerous lesions that are able to progress towards pancreatic ductal adenocarcinoma. We analyzed the expression of several claudin family members using surgical IPMN and MCN specimens to clarify the relationships between claudin expression and clinicopathological features. Twenty-nine and 25 consecutive cases of IPMN and MCN were selected and the expression of claudin-2, -4 and -18 was analyzed by immunohistochemistry. In addition, IPMN and MCN histological grade as well as IPMN subtypes were analyzed in relation to claudin expression. The 29 cases of IPMN comprised of 3 (10.3%) adenomas, 18 (62.1%) borderline malignancies and 8 (27.6%) carcinomas. The 25 cases of MCN comprised of 13 (52%) adenomas, 5 (20%) borderline malignancies and 7 (28%) carcinomas. Claudin-2, -4 and -18 showed strong expression both in IPMN and MCN, with the exception of claudin-4 in MCN. The expression grades of claudin-2 in both IPMN and MCN became weaker with increased histological grade. On the other hand, the expression grades of claudin-4 and -18 became stronger with increased histological grade in both IPMN and MCN. With regard to histological subtype, claudin-4 expression was the strongest in pancreatobiliary type IPMN, and claudin-18 expression was the strongest in gastric type IPMN. The distinct expression patterns of claudin-2, -4 and -18 suggest that claudins may serve as useful molecular markers for tumor differentiation and progression in IPMN and MCN.
Introduction
Recent advances in diagnostic imaging have resulted in more frequent detection of small pancreatic cystic lesions, such as serous cystic tumors, intraductal papillary mucinous neoplasms (IPMN), mucinous cystic neoplasms (MCN), and solid pseudo-papillary neoplasms (1, 2) . Of these pancreatic cystic lesions, mucinous tumors such as IPMN and MCN are considered definite premalignant lesions (3) . Because they show a broad spectrum of dysplasia, ranging from adenoma and borderline neoplasm to carcinoma, the identifying factors associated with the progression of non-invasive and/or invasive carcinoma is important (4, 5) . IPMN and MCN of the pancreas have similar histopathological characteristics. Nevertheless, they are clinically and epidemiologically quite different, and the relationships between them have long been a matter of discussion (2, 6, 7) .
Tight junctions are intercellular adhesion structures forming a permeability barrier at the apical surfaces of epithelia, and giving polarity to these cells (8) (9) (10) (11) . The claudin family of proteins is an essential component of the tight junction, consisting at least 23 transmembrane proteins (8) . The loss of claudins and other tight junction proteins in cancer has been interpreted as a mechanism for the loss of cell adhesion and as an important step in the progression of cancer to metastasis (12, 13) . Previous studies have shown that claudins are down-regulated or up-regulated in various cancers (14) (15) (16) (17) (18) (19) (20) (21) .
Microarray analysis (unpublished data) performed in our laboratory revealed differential expression of various tight junction proteins in IPMN and normal tissue. Among the tight junction proteins, claudin-2, 4, and -18 were significantly up-regulated in IPMN compared to normal tissue. This raised question about the differential expression patterns of those proteins in IPMN, MCN, and normal pancreas. The aims of this study were to analyze the expression patterns of claudin-2, -4 and -18 in mucinous tumors of the pancreas using surgical IPMN and MCN specimens to clarify the relationships between claudin expression and clinicopathological features such as histological grade and histological subtype. Table I . Among the 29 cases of IPMN, there were 2 (10.3%) adenomas, 18 (62.1%) borderline malignancies, and 8 (27.6%) carcinomas. Of the 29 cases of IPMN, 18 (62.1%) were gastric type, 9 (31%) were intestinal type, and 2 (6.9%) were pancreato-biliary type. Among the 25 cases of MCN, there were 13 (52%) adenomas, 5 (20%) borderline malignancies, and 7 (28%) carcinomas. MCN patients were predominantly female (87.5%, p<0.001) and were significantly younger (49±12.3 years vs. 61.9±6.8 years, p<0.001) than IPMN patients. MCNs were exclusively located in the body and tail of the pancreas, while IPMN localized primarily to the head (75.9%, p<0.001). MCN masses were significantly larger than IPMN masses (54.6±36.9 vs. 31.6±11.3 mm, P<0.001).
Results

Clinicopathological findings. Clinicopathological findings from 29 cases of IPMN and 25 cases of MCN are summarized in
Immunohistochemical findings. In normal human pancreatic tissue ( Fig. 1 ), claudin-2 showed weak membrane-bound, cytoplasmic granular staining in acinar cells, ductal cells, and islet cells. Claudin-4 showed strong membranous staining in Table I . Clinicopathological findings of patients with intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm (MCN) of the pancreas. 
acinar cells and ductal cells but not in islet cells. Claudin-18 staining was negative in ductal epithelium, acinar cells, or in islet cells.
The comparison of claudin immunohistochemistry with histological grade is summarized in Tables II and III. IPMNs were positive for claudin-2, -4 and -18 in 72.4, 89.7 and 96.6% of cases, respectively. MCNs were positive for clauding-2, -4 and -18 in 60.0, 44.0 and 96.0% of cases, respectively. There was a tendency for higher expression of all claudins tested in IPMN than in MCN. The expression of claudin-2 became weaker as the histological grade increased both in IPMN and MCN (IPMN, p=0.025; MCN, p=0.025). All 3 IPMN adenomas (100%) revealed strong claudin-2 expression, whereas 5 out of 8 IPMN carcinomas (62.5%) revealed negative expression for claudin-2 ( Fig. 2A-C) . For MCN, 8 out of 13 (61.5%) adenomas showed strong claudin-2 expression, whereas 6 out of 7 (85.7%) carcinomas showed negative for claudin-2 expression (Fig. 3A-C) . Contrary to claudin-2 expression, claudin-4 showed more robust expression as the histological grade increased both in IPMN and MCN (IPMN, p=0.001; MCN, p=0.001). While all 3 IPMN adenomas (100%) were negative for claudin-4, 6 out of 8 (75.0%) IPMN carcinomas were strongly positive for claudin-4 expression (Fig. 2D-F) . In MCN, 11 of 13 (84.6%) adenomas were negative for claudin-4, whereas 2 of 7 (28.6%) carcinomas showed strong claudin-4 expression (Fig. 3D-F) . The expression patterns of claudin-18 were similar to those of claudin-4 (IPMN, p=0.015; MCN, p=0.030). One of the 3 (33.3%) IPMN adenomas showed negative expression for claudin-18, whereas 7 of 8 (87.5%) IPMN carcinomas were strong positive for claudin-18 expression (Fig. 2G-I) . In MCN, 8 adenomas (61.5%) showed negative or weak for claudin-18 expression, whereas all 7 carcinomas (100%) showed strong claudin-18 expression (Fig. 3G-I) .
In some cases of IPMN and MCN which differ in grade of dysplasia in the same section, more advanced area, i.e. carcinoma revealed stronger expression for claudin-4 or -18 Table II . Claudin-2, -4, and -18 expression according to histological grade of IPMN. Claudin-18 Table III . Claudin-2, -4, and -18 expression according to histological grade of MCN. 
------------------------------------------------
MCN, mucinous cystic neoplasm. while more differentiated area showed weak or negative expression (Fig. 4) .
-------------------------------------------------Figure 2. Claudin-2, -4, and -18 expression in IPMN by immunochemistry. (A) Strong intensity claudin-2 staining in IPMN adenomas (score 2). (B) Weak intensity claudin-2 staining in borderline IPMN (score 1). (C) Negative claudin-2 staining in IPMN carcinoma (score 0). (D) Negative claudin-4 staining in IPMN adenomas (score 0). (E) Weak intensity claudin-4 staining in a borderline IPMN (score 1). (F) Strong intensity claudin-4 staining in an IPMN carcinoma (score 2). (G) Negative claudin-18 staining in an IPMN adenoma (score 0). (H) Weak intensity claudin-18 staining in a borderline IPMN (score 1). (I) Strong intensity claudin-18 staining in an IPMN carcinoma (score 2) (A-I, x400).
Histological subtypes of IPMN were categorized into gastric, intestinal, pancreato-biliary, or oncocytic (Fig. 5A ).
There were no cases of oncocytic IPMN in this study. Claudin-2 expression was stronger in intestinal type IPMN, although this was not statistically significant (p=0.374). The grade of claudin-4 expression was significantly higher in pancreato- biliary type IPMN (100%) (p=0.015), whereas claudin-18 expression was stronger in gastric type IPMN (p=0.023) (Fig. 5B) .
Discussion
In the present study, we investigated the expression pattern of tight junction proteins, claudin-2, -4, and -18 through immunohistochemical staining in surgically resected tissues of pancreatic mucinous tumors. Mucin-producing pancreatic tumors represented by IPMN and MCN are premalignant conditions and occasionally evolve into invasive carcinoma (3) . Although IPMN and MCN are histologically very similar to each other, these are definitely separate entities differing in gender predominance, age prevalence, and location of tumor within the pancreas (22, 23) .
IPMN is characterized by cystic dilatation of pancreatic ducts in which an intraductal proliferation of neoplastic mucinproducing cells is usually arranged in papillary patterns (24) . Although IPMNs are estimated to account for 5% of pancreatic neoplasms, they are not infrequently found on pancreatic imaging such as ultrasonography, computed tomography, and magnetic resonance imaging and thought to be more common than previously recognized (25) . MCN is presumably a de novo cystic tumor which gives rise to cystic dilatation of native ducts and characterized by an ovarian type of stroma. Although IPMN and MCN have some features that overlap, they can be distinguished by clinical, gross, and microscopic findings. While IPMN is more common in elderly male and often localizes in the head of pancreas, MCN occurs predominantly in perimenopausal female and localizes in the tail of pancreas (22, 23) . Whereas mucin-filled cysts of IPMN communicate with pancreatic ducts, MCN cysts typically do not communicate with the ductal system and often have thick walls. The presence of ovarian stroma is diagnostic for MCN and has almost become a requirement for the diagnosis of this tumor type (26) . Occasionally, it is difficult to differentiate both conditions solely based on histology, especially when ovarian type stroma is not seen in a suspected MCN case. Molecular features might be of help differentiating the diseases (2), however, there have been only a few reports and none of them have dealt with claudin proteins.
We aimed to find different features between IPMN and MCN at molecular level. In this study, however, both IPMN and MCN revealed similar patterns of claudin expression. Though majority of the mucinous tumors were reactive to claudin immunostaining, there were obvious differences of expression pattern according to the type of claudin proteins. While advanced histological lesions showed more robust expression of claudin-4 and -18, claudin-2 was predominantly expressed in benign adenomas. These findings were again supported by the findings that some cases having both borderline malignant and carcinoma lesions in the same section, tumor cells at carcinoma were positive for claudin-4 and -18, while tumor cells at borderline lesion showed weak or negative expression.
Claudins are essential components of tight junction that are critical for the maintenance of cellular integrity and polarity. Based on the role of claudins in the formation of tight junction, it has been hypothesized that the loss of claudin expression may reduce cell adhesion and thereby increase tumor cell motility and invasive potential (27) . Paradoxically, not only down-regulation but also up-regulation of claudins in many different cancers have been reported (14) (15) (16) (17) (18) (19) (20) (21) . Overexpression may allow the tumor cells to overcome the loss of cell adhesion resulting from the loss of other adhesion molecules (28) . Alternatively, up-regulation and/or aberrant expression of claudins may directly interfere with tight junction formation and function, thereby contributing to neoplastic transformation (29) . Up-regulation of claudins may also affect cell signaling pathways through their interactions with ZO-1, via binding domains at the carboxyl terminus. ZO-1 interacts with several signaling proteins associated with the neoplastic process, such as the Ras substrate AF-6, G proteins, and connexin 43 (30) . In a study using human ovarian surface epithelial cells that constitutively express wild-type claudin-3 and -4 (31), the overexpression of claudin-3 and -4 did not result in functional loss of tight junctions and they promoted invasiveness.
The high specificity of claudin expression in cancer may represent useful molecular markers for various cancers (8) . For example, a set of four markers, including claudin-3, was found to be sufficient to accurately identify all 158 ovarian cancers tested, including eight early-stage serous cancers (32) . In addition, claudin expression may be used as a prognostic indicator, like low claudin-1 expression is associated with a poor prognosis in stage II colon cancer (15) . Claudin-2 has been shown to be up-regulated in colorectal cancer (33) and closely correlated to gastric carcinogenesis (34) . Claudin-10 expression is also an independent prognostic factor for hepatocellular carcinoma recurrence after curative hepatectomy (35) . In particular, a series of previous studies demonstrated claudin-4 expression in pancreatic cancer and IPMN (18, 20, 36) . Moreover, targeting claudin-4 expressing tumors with Clostridium perfringens enterotoxin represented a promising new treatment modality for pancreatic cancer, and the data showed the feasibility of identifying new cancer treatment targets using highthroughput expression profiling analyses (17, 37) . In another study, claudin-18 was highly overexpressed in pancreatic infiltrating ductal adenocarcinoma as compared with the normal reactive ducts (37) . Claudin-18 was also up-regulated in gastric carcinoma (38) .
Although a number of studies demonstrated the implication of claudins in tumorigenesis including claudin-4 overexpression in IPMN, the expression of claudin-2 and -18 in IPMN and MCN has not been addressed. Among the 24 types of claudins, claudin-2 is unique in that its expression causes tight junctions to become leaky (39) , whereas other claudins seal up tight junctions. An earlier study showed that increased expression of claudin-2 in Madin-Darby canine kidney cells increased the leakiness of TJs (40) . These findings may explain the reciprocal changes of claudin-2 vs. claudin-4 and -18 expressions in pancreatic mucinous tumors in our study.
In this study, we also addressed the relationships between the histological subtypes of IPMN and claudin expression. The gastric type commonly forms branched duct-type IPMN with low-grade atypia thus harboring low malignant potential. Others more often present with marked atypia, mostly corresponding to borderline category or carcinoma, and are more aggressive (22, 41, 42) . In our study, 2 of 11 (18.2%) gastric types were adenomas and 4 of 5 (80%) pancreatobiliary types were carcinomas. Because the number of each histological subtype was too small and the oncocytic type was absent, these data did not represent the exact expression pattern of claudins according to sybtype of IPMN. As shown in Fig. 5 , however, claudin-2 was more often expressed in gastric (81.8%) and intestinal types (76.9%) compared to pancreato-biliary types (40%) (p=0.374), which suggests claudin-2 may be a marker of benign mucinous tumors of pancreas. Contrary to claudin-2, claudin-4 revealed robust expression in pancreato-biliary types (p=0.015). These findings suggest that the pattern of claudin expression can be useful in differentiating histological subtypes of IPMN.
In summary, our study suggests that pancreatic mucinous tumors, IPMN and MCN, frequently express claudin-2, -4 and -18 proteins. As the tumors advance, the expression level of claudin-4 and -18 increases, whereas claudin-2 decreases. Though further clarification needs to solve the role of claudins, this study suggests that claudins are involved in the tumorigenesis of pancreatic mucinous tumors and may be useful in differentiating histological grades and subtypes.
